Highbridge Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Highbridge Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-145,877	Closed	-$358K	–	1532
2015 Q4	$358K	Buy	145,877 +100,367	+221%	+$287K	0.01%	1116
2015 Q3	$137K	Buy	+45,510	New	+$196K	﹤0.01%	1413
2015 Q2	–	Sell	-14,728	Closed	-$64K	–	1437
2015 Q1	$64K	Sell	14,728 -34,035	-70%	-$123K	﹤0.01%	1333
2014 Q4	$145K	Buy	48,763 +27,765	+132%	+$76.2K	﹤0.01%	1087
2014 Q3	$70K	Buy	+20,998	New	+$54.9K	﹤0.01%	1159

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's CPRX Position: Q1 2016 in Review

Highbridge Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 145,877 shares — an estimated $358K sold.

Highbridge Capital Management first reported a position in CPRX in Q3 2014 and held it in 5 quarters. The position peaked at $358K in Q4 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

Highbridge Capital Management reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
Highbridge Capital Management sold 145,877 Catalyst Pharmaceutical shares in Q1 2016, an estimated $358K.
Highbridge Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2014 and held it in 5 quarters.
Highbridge Capital Management's Catalyst Pharmaceutical position peaked at $358K in Q4 2015.
73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Highbridge Capital Management's 13F filing for Q1 2016, filed 16 May 2016.